Drug Profile
KAN 101
Alternative Names: KAN-101Latest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator Kanyos Bio
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Coeliac disease
Most Recent Events
- 13 Dec 2023 Phase-II clinical trials in Coeliac disease (In the elderly, In adults) in USA (IV) (NCT06001177)
- 14 Oct 2023 Pharmacokinetics and pharmacodynamics data from a phase I ACeD trial in Coeliac disease presented at the 31st United European Gastroenterology Week (UEGW-2023)
- 21 Aug 2023 Anokion plans a phase II SynCeD trial in Coeliac disease in December 2023 (IV) (NCT06001177)